Stocklytics Platform
Asset logo for symbol INDP
Indaptus Therapeutics
INDP40
$1.20arrow_drop_up7.11%$0.08
Penny Stock
Asset logo for symbol INDP
INDP40

$1.20

arrow_drop_up7.11%

Performance History

Chart placeholder
Key Stats
Open$1.18
Prev. Close$1.17
EPS-1.86
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$11.82M
PE Ratio-
LOWHIGH
Day Range1.10
1.21
52 Week Range1.03
3.25
Ratios
Revenue-
EBITDA Margin %-
EPS-1.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Indaptus Therapeutics (INDP)

Indaptus Therapeutics, Inc. (INDP) is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of serious diseases. The company is dedicated to leveraging its expertise in the field of drug discovery and development to bring novel therapies to patients in need. With a strong pipeline of promising drug candidates, Indaptus Therapeutics is well-positioned for future growth and success. The company's commitment to scientific excellence and its passion for improving patient outcomes are driving forces behind its mission to transform the lives of patients around the world.
One of the key drivers of Indaptus Therapeutics' success is its innovative approach to drug development. The company's scientific team is comprised of leading experts in the field, who are constantly exploring new avenues and pushing the boundaries of scientific knowledge. By combining cutting-edge technologies with deep biological insights, Indaptus Therapeutics is able to identify and target novel disease pathways, leading to the development of highly effective therapies. This unique approach has earned the company recognition within the industry and has attracted collaborations with leading academic institutions and pharmaceutical companies.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jeffrey A. Meckler
Headquarters
New York
Employees
6
Exchange
NASDAQ
add Indaptus Therapeutics to watchlist

Keep an eye on Indaptus Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Indaptus Therapeutics's (INDP) price per share?

The current price per share for Indaptus Therapeutics (INDP) is $1.21. The stock has seen a price change of $0.08 recently, indicating a 7.11% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Indaptus Therapeutics (INDP)?

For Indaptus Therapeutics (INDP), the 52-week high is $3.25, which is 169.71% from the current price. The 52-week low is $1.03, the current price is 16.99% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Indaptus Therapeutics (INDP) a growth stock?

Indaptus Therapeutics (INDP) has shown an average price growth of -6.65% over the past three years. It has received a score of 15 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Indaptus Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Indaptus Therapeutics (INDP) stock price performance year to date (YTD)?

As of the latest data, Indaptus Therapeutics (INDP) has a year-to-date price change of -31.53%. Over the past month, the stock has experienced a price change of -15.73%. Over the last three months, the change has been -26.97%. Over the past six months, the figure is -49.79%.
help

Is Indaptus Therapeutics (INDP) a profitable company?

Indaptus Therapeutics (INDP) has a net income of -$15.42M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$16.38M. Furthermore, the EBITDA is -$16.48M.
help

What is the market capitalization of Indaptus Therapeutics (INDP)?

Indaptus Therapeutics (INDP) has a market capitalization of $11.32M. The average daily trading volume is 1.13, indicating the stock's liquidity and investor engagement.

News

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
INDAPTUS THERAPEUTICS
DECOY20
PHASE 1 TRIAL
SAFETY DATA
PD-1 INHIBITOR
Nov 7, 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
EARNINGS RELEASES AND OPERATING RESULTS
May 8, 2024

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
HEALTH
CLINICAL STUDY
Apr 11, 2024

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
CALENDAR OF EVENTS
Mar 25, 2024

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
EARNINGS RELEASES AND OPERATING RESULTS
Mar 13, 2024

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
HEALTH
CLINICAL STUDY
Mar 4, 2024

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level